Jump to content

Promestriene

From Wikipedia, the free encyclopedia
(Redirected from Colpotrophin)
Promestriene
Clinical data
Trade namesColpotrofin, Colpotrophine, Delipoderm
Other namesEstradiol 3-propyl 17β-methyl diether; 17β-Methoxy-3-propoxyestra-1,3,5(10)-triene
Routes of
administration		Topical
Drug classEstrogen; Estrogen ester
ATC code
Identifiers
  • (8R,9S,13S,14S)-17-methoxy-13-methyl-3-propoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.049.401 Edit this at Wikidata
Chemical and physical data
FormulaC22H32O2
Molar mass328.496 g·mol−1
3D model (JSmol)
  • CCCOc1ccc2c(c1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4OC)C
  • InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21?,22+/m1/s1 ☒N
  • Key:IUWKNLFTJBHTSD-QIKJAYGVSA-N ☒N
  (verify)

Promestriene (INNTooltip International Nonproprietary Name) (brand names Colpotrofin, Colpotrophine, Delipoderm), also known as estradiol 3-propyl 17β-methyl diether, is a synthetic estrogen which is used topically in a 1% cream formulation for the treatment of vaginal atrophy in women.[1][2][3][4][5] It is the 3-propyl and 17β-methyl diether of estradiol and does not appear to convert into estradiol in the body.[1][6] Promestriene is minimally absorbed and appears to have negligible systemic estrogenic effect.[1] The drug has been described as a tropic agent and antiseborrheic.[2] It has not been found to be effective in the treatment of pattern hair loss or other conditions of cutaneous androgenization.[7][8] Promestriene was first introduced in France in 1974 and has been marketed in 34 countries worldwide.[1] It has been used in millions of women.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P, Berretta M (November 2013). "Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?". Anti-Cancer Drugs. 24 (10): 989–998. doi:10.1097/CAD.0b013e328365288e. PMID 24080714. S2CID 3458356.
  2. ^ a b Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1671–. ISBN 978-0-412-46630-4.
  3. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 1248, 1266, 1318, 1557. ISBN 978-3-88763-075-1.
  4. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 270–271. ISBN 978-0-8155-1856-3.
  5. ^ Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 289, 33 2. ISBN 978-3-7692-2114-5.
  6. ^ Santos I, Clissold S (September 2010). "Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy". Gynecological Endocrinology. 26 (9): 644–651. doi:10.3109/09513591003767948. PMID 20374067. S2CID 243338.
  7. ^ Orfanos CE, Montagna W, Stüttgen G (6 December 2012). Hair Research: Status and Future Aspects; Proceedings of the First International Congress on Hair Research, Hamburg, March 13th–16, 1979. Springer Science & Business Media. pp. 553–. ISBN 978-3-642-81650-5.
  8. ^ Beylot C (1 October 1998). "Menopause, Skin, and Cosmetology". In Baran R, Maibach HI (eds.). Textbook of Cosmetic Dermatology. CRC Press. pp. 493–. ISBN 978-1-85317-478-0.
Stub icon

This article about a steroid is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wiki.x.io/w/index.php?title=Promestriene&oldid=1188082821"